ArticleInfection and drug resistance2025
From Screening to Strategy: Targeted Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Prediction After Endoscopic Retrograde Cholangiopancreatography (ERCP).
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invariably, patients can be exposed to Carbapenem-resistant Enterobacteriaceae (CRE) through contaminated device during Endoscopic retrograde cholangiopancreatography (ERCP). We aimed to identify the risk factors and establish a model for predicting subsequent CRE infections in patients with CRE-positive bile screening after ERCP. Methods: Patients underwent ERCP were performed with bile active screening of CRE. Medical records were reviewed to identify patient demographics, comorbidities, microbiology and antimicrobial treatments. The results were grouped according to the occurrence of subsequent CRE infection, and the patients were divided into two groups: a CRE infection group and a non-CRE infection group. The diagnosis for CRE infection was confirmed by more than 2 physicians. Logistic regression methods were used to determine the risk factors for CRE infections. The risk prediction model was constructed by integrating the clinical data and the result of logistic regression, by a nomogram and forest plot. Finally, goodness of fit of the final model was tested using the likelihood ratio test. Results: Central venous catheterization (OR=11.32; 95% CI 1.15-40.62), cholecystitis (OR=3.82; 95% CI 1.12-13.01), malignancy (OR=4.33; 95% CI 1.41-13.35) and the antimicrobial drug use (OR=1.08; 95% CI 1.03-1.14) were considered as highly relevant risk factors for subsequent CRE infections in bile active screening positive patients. The goodness of fit test indicated that the model was well-calibrated for both groups. Conclusion: A targeted active screening in bile samples can be beneficial for patients with high risk factors of CRE infections. The nomogram developed in this study can help clinicians accurately predict the possibility of patients with subsequent CRE infections after ERCP, so as to facilitate more precise individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.